Netherlands Depression Therapeutics Market Analysis

Netherlands Depression Therapeutics Market Analysis


$ 3999

Netherlands' depression therapeutics market is expected to grow from $26 Mn in 2022 to $41 Mn in 2030 with a CAGR of 5.7% for the forecasted year 2022-30. Supportive government policies in the Netherlands related to depression and mental health as well as new and innovative technological advancements in the treatment of depression have led to the development of the market. The Netherlands' depression therapeutics market is segmented by drug type, therapies, indication, and end users. Xenikos, Dannalab, and Pfizer are the major players in the Netherlands' depression therapeutics market.

ID: IN10NLPH034 CATEGORY: Pharmaceuticals GEOGRAPHY: Netherlands AUTHOR: Dr. Parul Choudhary

Buy Now

Netherlands Depression Therapeutics Market Executive Analysis

Netherlands' depression therapeutics market is expected to grow from $26 Mn in 2022 to $41 Mn in 2030 with a CAGR of 5.7% for the forecasted year 2022-30. The Netherlands has long been a supporter of global health and human rights, and it has taken the lead in defending access to the full range of sexual and reproductive health services as well as mental health and psychosocial care, including for those in vulnerable groups and those experiencing humanitarian crises. WHO and the Netherlands have established a long-standing strategic collaboration, building on the Netherlands' significant contribution to the global promotion of health and wellbeing. In total, the Netherlands contributed nearly $94 Mn to assist the work of WHO in 2020–2021, of which $80 Mn came from voluntary donations, including more than $11 Mn to support the COVID–19 response and $8 Mn to the Contingency Fund for Emergencies (CFE).

In the Netherlands, 19.3% of adults have experienced a mood disorder at some time in their lives, and 12.4% of all adults have experienced an anxiety disorder in the past year. Each year, more than 700.000 individuals suffer from depression. Approximately 15% of senior Dutch individuals exhibit clinically significant depressive symptoms.

Depression is a mood condition that causes constant gloom, loss of vigour, and interest loss. These signs may appear infrequently or continuously. Clinical depression or Major Depressive Disorder are the terms used by experts to describe this illness. The symptoms of depression differ from normal sadness in that they last longer than a few weeks and interfere with your daily living. For the management of mental health issues, psilocybin therapy is a method being researched. It blends psychological support with the psychoactive drug psilocybin's pharmacological benefits. Some kinds of mushrooms, also known as "magic mushrooms," contain psilocybin as an active component. We are researching the efficacy of psilocybin therapy, originally in treatment-resistant depression, and have created a synthesized formulation of the drug called COMP360. When given psychological support from particularly qualified therapists, early studies carried out in pioneering academic centres in the Netherlands have shown signals that psilocybin may be a safe and effective medication for patients with depression, anxiety, addiction, and other mental illnesses. In the Netherlands, a ground-breaking depression treatment facility has been launched. Psilocybin is used by the Synthesis Centre to aid patients suffering from depression and other mental illnesses. In the Netherlands, psilocybin, which is derived from various fungi types, is permitted. However, it has mainly been used there for recreational purposes, much like marijuana, which has been legal in the area for decades.

Netherlands Depression Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

The way the Netherlands government views mental health treatment is evolving. The provision of general healthcare now includes mental healthcare. The diagnosis and treatment of psychiatric disorders are being improved with the introduction of evidence-based programs and standards, both in primary care and specialist care, as well as the implementation of a "stepped care" system. New mental healthcare organizations are being enticed to join the mental health market, and competition between providers of care will be encouraged. This competition's goals are to increase care quality while lowering expenses. These changes are resulting in the expansion of the Netherlands' depression therapeutics market. The Netherlands' depression therapeutics market is expanding as a result of new antidepressant medications and other therapies for depression being developed, as well as improvements in delivery systems and diagnostic equipment.

Market Restraints

The cost of benzodiazepines and antidepressants is a significant burden on the Netherlands' health care system. According to some reports, doctors are increasingly prescribing antidepressants, particularly for people with milder depression symptoms who are not getting psychotherapy. Although these medications are beneficial for many patients, they can also have a number of negative side effects if administered incorrectly. In addition to dependence and sedation, benzodiazepines have also been linked to memory loss, impaired alertness and equilibrium, postural hypotension, risk of falling, and withdrawal symptoms. Antidepressant side effects are being reported in an increasing number of research, particularly among non-severe cases which have been limiting the growth of the Netherlands depression therapeutics market.

Competitive Landscape

Key Players

  • Kiadis Pharma (NLD)
  • Synerkine Pharma (NLD)
  • Northsea Therapeutics (NLD)
  • Xenikos (NLD)
  • Dannalab (NLD)
  • Pfizer
  • Mylan
  • Novartis
  • Hikma Pharmaceuticals
  • Aurobindo Pharma
  • AbbVie
  • Melinta Therapeutics
  • Bristol-Myers Squibb
  • GSK
  • Bayer

Healthcare Policies and Regulatory Landscape

The Netherlands' Minister of Health is responsible for overseeing mental health services. Government policy has been established on ideas like continuity of care since the late 1990s. The creation of integrated mental healthcare facilities was the result of collaboration between clinical and ambulatory care. A sizable portion of mental healthcare will be integrated into the health insurance system and funded similarly to how physical healthcare is paid for. The basis for payments will be "diagnosis treatment combinations." (Diagnose Behandel Combinaties, DBCs). The Exceptional Health Expenses Act will only be used to reimburse hospital stays longer than 12 months. The Zorgverzekeringswet, the nation's public health insurance program, covers depression therapeutics in the Netherlands. (Zvw). For eligible patients who meet certain requirements and limitations, the Zvw will pay for depression drugs.

The Dutch Healthcare Authority (NZa) establishes the reimbursement list, which contains a variety of depression treatments like antidepressant drugs and psychotherapy services. The list details the requirements for payment, including the maximum amount that may be reimbursed for each therapy session and the maximum length of treatment. The Netherlands Healthcare Institute advises the Ministry of Health on coverage decisions, and some medications must be covered by that ministry (Zorginstituut Nederland). While insurers and manufacturers negotiate drug prices, and insurers can adjust drug deductibles based on value, the government protects against monopoly drug pricing by establishing price ceilings.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Depression Therapeutics Segmentation

By Drug Type (Revenue, USD Billion):

  • Antidepressants
  • Anxiolytics
  • Anticonvulsants
  • Noradrenergic Agents
  • Atypical Antipsychotics

By Therapies (Revenue, USD Billion):

  • Electroconvulsive Therapy (ECT)
  • Cognitive Behaviour Therapy (CBT)
  • Psychotherapy
  • Deep Brain Stimulation
  • Transcranial Magnetic Stimulation (TMS)
  • Cranial electrotherapy stimulation (CES)

By Indication (Revenue, USD Billion):

  • Major Depressive Disorder (MDD)
  • Bipolar Disorder
  • Dysthymic Disorder
  • Postpartum Depression
  • Seasonal Affective Disorder (SAD)
  • Premenstrual Dysphoric Disorder (PMDD)
  • Others

By End Users (Revenue, USD Billion):

  • NGOs
  • Asylums
  • Hospitals
  • Mental Healthcare Centers

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Xenikos, Dannalab, and Pfizer are the major players in the Netherlands' depression therapeutics market.

The Netherlands' depression therapeutics market is expected to grow from $26 Mn in 2022 to $41 Mn in 2030 with a CAGR of 5.7% for the forecasted year 2022-2030.

The Netherlands' depression therapeutics market is segmented by drug type, therapies, indication, and by end users.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 09 October 2023
Updated by: Riya Doshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up